

## **SUPPLEMENTAL INFORMATION**

### **Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder**

Holmes *et al.*

### **Supplemental statistics: power calculations**

All power calculations were conducted using G\*Power (version 3.1.9.6). After completing multivariate tests evaluating group differences in  $V_T$  for the three prefrontal ROIs, we performed power calculations to determine achieved power ( $1-\beta$ ). Results of these analyses suggest we were sufficiently powered ( $1-\beta>0.8$ ) to detect a main effect of diagnosis between the three primary diagnostic groups (HC, BD, and MDD):

Sample size (N)=62  
Groups=3  
Response variables=3  
Observed effect size ( $f^2$ )=0.1198  
Error probability ( $\alpha$ )=0.05  
**Estimated power ( $1-\beta$ )=0.815**

However, we did not achieve sufficient power to detect a main effect of diagnosis between the four diagnostic groups (HC, BD-dep, BD-euth, and MDD):

Sample size (N)=62  
Groups=4  
Response variables=3  
Observed effect size ( $f^2$ )=0.0834  
Error probability ( $\alpha$ )=0.05  
**Estimated power ( $1-\beta$ )=0.772**

For the exploratory correlation analyses, we used our observed effect sizes (correlation coefficients, r), to compute required sample sizes that would be required for adequately powered ( $1-\beta>0.8$ ) two-tailed tests:

| ROI $V_T$ vs. depression severity (MADRS) in <b>BD-dep</b>      | ROI $V_T$ vs. depression severity (MADRS) in <b>MDD</b>         |
|---|---|
| Observed effect size (r)=0.1*                                   | Observed effect size (r)=0.6*                                   |
| Error probability ( $\alpha$ )=0.05                             | Error probability ( $\alpha$ )=0.05                             |
| Actual power ( $1-\beta$ )=0.800                                | Actual power ( $1-\beta$ )=0.824                                |
| <b>Required sample size (n)=779</b><br>(Actual sample size =27) | <b>Required sample size (n)=17</b><br>(Actual sample size =17)  |
| ROI $V_T$ vs. cognitive function in <b>BD-dep</b>               | ROI $V_T$ vs. cognitive function in <b>MDD</b>                  |
| Observed effect size (r)=0.4†                                   | Observed effect size (r)=0.2†                                   |
| Error probability ( $\alpha$ )=0.05                             | Error probability ( $\alpha$ )=0.05                             |
| Actual power ( $1-\beta$ )=0.807                                | Actual power ( $1-\beta$ )=0.801                                |
| <b>Required sample size (n)=44</b><br>(Actual sample size =27)  | <b>Required sample size (n)=191</b><br>(Actual sample size =17) |

\*The lowest ROI with the smallest effect size was used

†The ROI and cognitive domain (psychomotor processing or executive function) combination yielding the smallest effect size was used

**Supplemental tables**

**Table S1.** Details of psychiatric medications across subjects. Each row represents the reported medication list for a single subject.

| <b>Diagnostic Group</b> | <b>List of current psychiatric medications</b>       |
|-------------------------|--|
| BD-euth                 | Gabapentin, Lithium, Melatonin, Paliperidone,        |
| BD-euth                 | Amphetamine/dextroamphetamine, Aripiprazole          |
| BD-euth                 | Quetiapine   |
| BD-dep                  | Citalopram   |
| BD-dep                  | Amphetamine/dextroamphetamine, Ziprasidone           |
| BD-dep                  | Amphetamine/dextroamphetamine                        |
| BD-dep                  | Alprazolam   |
| MDD                     | Amphetamine/dextroamphetamine, Bupropion, Clonazepam |
| MDD                     | Buspirone, Escitalopram, Risperidone                 |
| MDD                     | Amphetamine/dextroamphetamine XR, Vortioxetine       |
| MDD                     | Buspirone, Duloxetine                                |

**Table S2.** MANCOVA of [<sup>18</sup>F]FPEB  $V_T$  within PFC subregions across diagnostic groups (HC, MDD, BD), with psychiatric medication status as a covariate.

| <b>Multivariate Tests*</b>              |                    |   |                |
|---|--------------------|---|----------------|
|   | <b>Effect</b>      | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
|   | Group              | 2.4 (6, 108.0)                            | 0.033          |
|   | Current psych meds | 2.7 (3, 54)                               | 0.053          |
| <b>Tests of Between-Subject Effects</b> |                    |   |                |
| <b>Dependent Variable</b>               | <b>Source</b>      | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
| OFC                                     | Group              | 5.6 (2, 56)                               | 0.006          |
|   | Current psych meds | 6.6 (1, 56)                               | 0.013          |
| vmPFC                                   | Group              | 6.1 (2, 56)                               | 0.004          |
|   | Current psych meds | 6.6 (1, 56)                               | 0.013          |
| dIPFC                                   | Group              | 7.4 (2, 56)                               | 0.001          |
|   | Current psych meds | 5.1 (1, 56)                               | 0.028          |

\*Wilks' Lambda, exact statistic

**Table S3.** MANCOVA of [<sup>18</sup>F]FPEB  $V_T$  within PFC subregions across diagnostic groups (HC, MDD, BD-dep, and BD-euth), with psychiatric medication status as a covariate.

| <b>Multivariate Tests*</b>              |                    |   |                |
|---|--------------------|---|----------------|
|   | <b>Effect</b>      | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
|   | Group              | 1.5 (9, 129.1)                            | 0.115          |
|   | Current psych meds | 2.6 (3, 53)                               | 0.060          |
| <b>Tests of Between-Subject Effects</b> |                    |   |                |
| <b>Dependent Variable</b>               | <b>Source</b>      | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
| OFC                                     | Group              | 3.7 (3, 55)                               | 0.017          |
|   | Current psych meds | 6.4 (1,55)                                | 0.014          |
| vmPFC                                   | Group              | 4.1 (3, 55)                               | 0.011          |
|   | Current psych meds | 6.4 (1,55)                                | 0.014          |
| dIPFC                                   | Group              | 4.8 (3, 55)                               | 0.005          |
|   | Current psych meds | 5.0 (1,55)                                | 0.030          |

\*Wilks' Lambda, exact statistic

**Table S4.** MANCOVA of [<sup>18</sup>F]FPEB  $V_T$  within PFC subregions across diagnostic groups (HC, MDD, BD), with venous vs. arterial-derived input function as a covariate.

| <b>Multivariate Tests*</b>              |                     |   |                |
|---|---------------------|---|----------------|
|   | <b>Effect</b>       | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
|   | Group               | 2.1 (6, 112)                              | 0.055          |
|   | Arterial vs. venous | 2.5 (3, 56)                               | 0.069          |
| <b>Tests of Between-Subject Effects</b> |                     |   |                |
| <b>Dependent Variable</b>               | <b>Source</b>       | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
| OFC                                     | Group               | 3.5 (2, 58)                               | 0.037          |
|   | Arterial vs. venous | 6.8 (1, 58)                               | 0.012          |
| vmPFC                                   | Group               | 3.9 (2, 58)                               | 0.027          |
|   | Arterial vs. venous | 6.6 (1, 58)                               | 0.013          |
| dlPFC                                   | Group               | 5.4 (2, 58)                               | 0.007          |
|   | Arterial vs. venous | 5.4 (1, 58)                               | 0.023          |

\*Wilks' Lambda, exact statistic

**Table S5.** MANCOVA of [<sup>18</sup>F]FPEB  $V_T$  within PFC subregions across diagnostic groups (HC, MDD, BD-dep, and BD-euth), with venous vs. arterial-derived input function as a covariate.

| <b>Multivariate Tests*</b>              |                     |   |                |
|---|---------------------|---|----------------|
|   | <b>Effect</b>       | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
|   | Group               | 1.4 (9, 134)                              | 0.177          |
|   | Arterial vs. venous | 2.3 (3, 55)                               | 0.083          |
| <b>Tests of Between-Subject Effects</b> |                     |   |                |
| <b>Dependent Variable</b>               | <b>Source</b>       | <b>F (DF<sub>H</sub>, DF<sub>E</sub>)</b> | <b>p-value</b> |
| OFC                                     | Group               | 2.3 (3, 57)                               | 0.087          |
|   | Arterial vs. venous | 6.5 (1,57)                                | 0.014          |
| vmPFC                                   | Group               | 2.5 (3, 57)                               | 0.066          |
|   | Arterial vs. venous | 6.3 (1,57)                                | 0.015          |
| dlPFC                                   | Group               | 3.5 (3, 57)                               | 0.021          |
|   | Arterial vs. venous | 5.3 (1,57)                                | 0.025          |

\*Wilks' Lambda, exact statistic

**Table S6.** Mean [<sup>18</sup>F]FPEB  $V_T$  values and ANOVA results for brain regions not included in the primary analysis for HC, BD, and MDD groups.

| Brain Region         | Group Mean(SD) |             |             | Univariate Tests  |              |
|----------------------|----------------|-------------|-------------|-------------------|--------------|
|                      | HC (n=18)      | BP (n=27)   | MDD (n=17)  | F <sub>2,59</sub> | p-value      |
| Amygdala             | 30.46(7.68)    | 26.70(5.11) | 30.74(6.45) | 2.919             | 0.062        |
| Caudate              | 34.74(9.57)    | 29.15(5.93) | 34.25(6.56) | <b>4.101</b>      | <b>0.022</b> |
| Cerebellum           | 12.69(2.75)    | 10.60(2.26) | 12.37(4.12) | 3.118             | 0.052        |
| Cingulate, anterior  | 37.61(7.92)    | 32.28(6.49) | 38.31(7.40) | <b>4.803</b>      | <b>0.012</b> |
| Cingulate, posterior | 27.02(8.23)    | 22.35(7.04) | 25.35(3.78) | 2.779             | 0.07         |
| Hippocampus          | 27.80(6.24)    | 24.52(4.75) | 28.16(5.55) | 3.097             | 0.053        |
| Insula, anterior     | 36.86(8.30)    | 32.28(6.63) | 37.32(8.08) | 3.044             | 0.056        |
| Insula, posterior    | 34.40(8.10)    | 29.72(5.69) | 34.77(7.94) | <b>3.527</b>      | <b>0.036</b> |
| Occipital cortex     | 31.96(6.62)    | 28.18(5.94) | 32.02(6.25) | 2.843             | 0.066        |
| Parietal cortex      | 31.02(10.52)   | 29.05(5.76) | 33.80(6.94) | 1.98              | 0.147        |
| Putamen              | 33.73(7.76)    | 28.95(5.51) | 33.19(6.13) | <b>3.809</b>      | <b>0.028</b> |
| Temporal cortex      | 35.17(8.90)    | 31.26(6.15) | 36.71(7.76) | 3.142             | 0.051        |
| Thalamus             | 23.63(4.02)    | 19.78(3.81) | 22.21(4.08) | <b>5.465</b>      | <b>0.007</b> |

**Table S7.** Mean [<sup>18</sup>F]FPEB  $V_T$  values and ANOVA results for brain regions not included in the primary analysis for HC, BD-euth, BD-dep, and MDD groups.

| Brain Region         | Group Mean(SD) |                |               |             | Univariate Tests  |              |
|----------------------|----------------|----------------|---------------|-------------|-------------------|--------------|
|                      | HC (n=18)      | BP-euth (n=10) | BP-dep (n=17) | MDD (n=17)  | F <sub>3,58</sub> | p-value      |
| Amygdala             | 30.46(7.68)    | 26.62(4.89)    | 26.75(5.38)   | 30.74(6.45) | 1.914             | 0.137        |
| Caudate              | 34.74(9.57)    | 29.21(4.85)    | 29.11(6.63)   | 34.25(6.56) | 2.688             | 0.055        |
| Cerebellum           | 12.69(2.75)    | 11.33(2.03)    | 10.21(2.34)   | 12.37(4.12) | 2.34              | 0.083        |
| Cingulate, anterior  | 37.61(7.92)    | 32.53(5.18)    | 32.13(7.30)   | 38.31(7.40) | <b>3.156</b>      | <b>0.031</b> |
| Cingulate, posterior | 27.02(8.23)    | 20.97(7.86)    | 23.16(6.63)   | 25.35(3.78) | 2.062             | 0.115        |
| Hippocampus          | 27.80(6.24)    | 24.60(5.01)    | 24.48(4.76)   | 28.16(5.55) | 2.031             | 0.12         |
| Insula, anterior     | 36.86(8.30)    | 33.19(5.69)    | 31.74(7.24)   | 37.32(8.08) | 2.078             | 0.114        |
| Insula, posterior    | 34.40(8.10)    | 30.07(5.14)    | 29.51(6.14)   | 34.77(7.94) | 2.324             | 0.085        |
| Occipital cortex     | 31.96(6.62)    | 28.53(5.24)    | 27.98(6.46)   | 32.02(6.25) | 1.881             | 0.143        |
| Parietal cortex      | 31.02(10.52)   | 29.99(5.64)    | 28.50(5.93)   | 33.80(6.94) | 1.38              | 0.258        |
| Putamen              | 33.73(7.76)    | 29.10(4.84)    | 28.86(6.01)   | 33.19(6.13) | 2.499             | 0.069        |
| Temporal cortex      | 35.17(8.90)    | 31.83(5.48)    | 30.93(6.65)   | 36.71(7.76) | 2.093             | 0.111        |
| Thalamus             | 23.63(4.02)    | 20.23(3.97)    | 19.52(3.80)   | 22.21(4.08) | <b>3.66</b>       | <b>0.018</b> |

**Supplemental Figure 1.** MANOVA of  $[^{18}\text{F}]$ FPEB  $V_T$  within PFC subregions across HC (black), MDD (orange), and BD groups (purple) ( $F_{6,116}=2.175, p=0.050$ ). Brackets indicate  $p$ -values from independent-sample t-tests. Individual values are depicted with group mean $\pm$ SD.

